Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 21 years old.
- You have a newly diagnosed high-grade glioma (including DIPG) with an ALK or ROS-1 fusion.
- You have not received any chemotherapy or other cancer treatment before this study.
- You are able to take pills by mouth and do not have a condition that interferes with absorption.
- You have adequate organ function (bone marrow, kidney, liver, lungs, heart) as determined by tests.
- If you are female and of childbearing potential, you agree to use effective non-hormonal birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
This trial tests a combination of two immunotherapy drugs, relatlimab and nivolumab, for people with certain brain tumors (high-grade glioma or DIPG) that have DNA repair issues. The treatment aims to help the immune system fight the tumor.
This study tests an oral drug called lorlatinib in people with ROS1-positive lung cancer that has spread to the brain. The drug targets the ROS1 mutation and aims to shrink brain tumors and improve outcomes.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.